Bioline Rx Ltd Adr (BLRX)

Dec 16, 2024

BioLineRx stock hits 52-week low at $0.21 amid market challenges - Investing.com

Dec 16, 2024

Dec 06, 2024

BioLineRx stock plunges to 52-week low, hits $0.25 - Investing.com India

Dec 06, 2024

Nov 26, 2024

BioLineRx stock target cut, retains buy on Q3 financial results - Investing.com

Nov 26, 2024

Nov 25, 2024

BioLineRx Reports Strategic Moves in Q3 2024 - TipRanks

Nov 25, 2024

Nov 25, 2024

BioLineRx earnings beat by $0.04, revenue topped estimates By Investing.com - Investing.com South Africa

Nov 25, 2024

Nov 25, 2024

BioLineRx earnings beat by $0.04, revenue topped estimates - Investing.com India

Nov 25, 2024

Nov 25, 2024

Earnings call: BioLineRx announces Q3 results and strategic shifts - Investing.com

Nov 25, 2024

Nov 25, 2024

Earnings call: BioLineRx announces Q3 results and strategic shifts By Investing.com - Investing.com South Africa

Nov 25, 2024

Nov 25, 2024

BioLineRx Secures Key Deals to Boost Shareholder Value - TipRanks

Nov 25, 2024

Nov 25, 2024

IO Biotech Inc (NASDAQ: IOBT) Is A Buzzing Hot Stock - Stocks Register

Nov 25, 2024

Nov 22, 2024

BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell - Yahoo Finance

Nov 22, 2024

Nov 21, 2024

BioLineRx stock hits 52-week low at $0.38 amid market challenges - Investing.com

Nov 21, 2024

Nov 21, 2024

BiolineRx Ltd. Announces New Direct Offering of Shares - TipRanks

Nov 21, 2024

Nov 21, 2024

SEC Form 424B5 filed by BioLineRx Ltd. - Quantisnow

Nov 21, 2024

Nov 20, 2024

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 - Benzinga

Nov 20, 2024

Nov 12, 2024

BioLineRx Granted Extension to Meet Nasdaq Requirements - TipRanks

Nov 12, 2024

Nov 05, 2024

BioLineRx’s Motixafortide Shows Promise in Sickle Cell Trials - TipRanks

Nov 05, 2024

Oct 24, 2024

BioLineRx stock hits 52-week low at $0.39 amid market challenges - Investing.com India

Oct 24, 2024

Oct 16, 2024

BioLineRx Secures Extended U.S. Patent for Motixafortide - TipRanks

Oct 16, 2024

Oct 16, 2024

BioLineRx secures US patent for cancer drug motixafortide - Investing.com

Oct 16, 2024

Oct 16, 2024

BioLineRx secures US patent for cancer drug motixafortide By Investing.com - Investing.com UK

Oct 16, 2024

Oct 15, 2024

BioLineRx stock hits 52-week low at $0.43 amid market challenges - Investing.com

Oct 15, 2024

Oct 07, 2024

Riding the Waves: A Guide to Investing in BLRX Stock - The InvestChronicle

Oct 07, 2024

Oct 07, 2024

Market Insight: Bioline Rx Ltd ADR (BLRX)’s Notable Drop, Closing at 0.46 - The Dwinnex

Oct 07, 2024

Oct 02, 2024

BioLineRx stock hits 52-week low at $0.5 amid market challenges - Investing.com

Oct 02, 2024

Oct 01, 2024

BioLineRx Ltd. Shareholders Approve Key Resolutions - TipRanks

Oct 01, 2024

Oct 01, 2024

Bioline Rx Ltd ADR (BLRX) Stock: A Year of Market Fluctuations - The InvestChronicle

Oct 01, 2024

Oct 01, 2024

Stock Market Recap: Bioline Rx Ltd ADR (BLRX) Concludes at 0.54, a -13.53 Surge/Decline - The Dwinnex

Oct 01, 2024

Sep 02, 2024

A new trading data show Bioline Rx Ltd ADR (BLRX) is showing positive returns. - SETE News

Sep 02, 2024

Sep 02, 2024

Metric Analysis: Bioline Rx Ltd ADR (BLRX)’s Key Ratios in the Limelight - The Dwinnex

Sep 02, 2024

Sep 02, 2024

BLRX overperforms with a 0.95 increase in share price - US Post News

Sep 02, 2024

Aug 23, 2024

Australia Single Molecule, Real-Time (SMRT) Sequencing Market Size & Outlook, 2030 - Grand View Research

Aug 23, 2024

Aug 19, 2024

BioLineRx Schedules Annual Shareholders Meeting - TipRanks

Aug 19, 2024

Aug 16, 2024

Financial Analysis: Bioline Rx Ltd ADR (BLRX)’s Ratios Unveil Key Insights - The Dwinnex

Aug 16, 2024

Aug 16, 2024

BLRX Stock: Exploring Bioline Rx Ltd ADR’s Growth - The InvestChronicle

Aug 16, 2024

Aug 16, 2024

Earnings call: BioLineRx beats Q2 goals with strong APHEXDA demand - Investing.com

Aug 16, 2024

Aug 15, 2024

BioLineRx’s Strong Quarter with APHEXDA Growth - TipRanks

Aug 15, 2024

Aug 15, 2024

Options Volatility and Implied Earnings Moves Today, August 15, 2024 - TipRanks

Aug 15, 2024

Jul 30, 2024

Bioline Rx Ltd ADR’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle

Jul 30, 2024

Jul 30, 2024

Ratio Revelations: Bioline Rx Ltd ADR (BLRX)’s Financial Metrics in the Spotlight - The Dwinnex

Jul 30, 2024

Jul 18, 2024

There is no doubt that Bioline Rx Ltd ADR (BLRX) ticks all the boxes. - SETE News

Jul 18, 2024

Jul 17, 2024

Bioline Rx Ltd ADR (BLRX) stock analysis: A simple moving average approach - US Post News

Jul 17, 2024

Jul 11, 2024

BLRX’s Stock Journey: What Investors Need to Know About Bioline Rx Ltd ADR’s Performance - The InvestChronicle

Jul 11, 2024

Jul 04, 2024

Financial Analysis: Bioline Rx Ltd ADR (BLRX)'s Ratios Unveil Key Insights – DWinneX - The Dwinnex

Jul 04, 2024

May 30, 2024

BioLineRx Trials New Sickle Cell Gene Therapy - TipRanks

May 30, 2024

May 30, 2024

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applicatio - Investing.com India

May 30, 2024

May 29, 2024

Earnings call: BioLineRx Q1 2024 results show steady progress By Investing.com - Investing.com

May 29, 2024

May 29, 2024

Earnings call: BioLineRx Q1 2024 results show steady progress - Investing.com

May 29, 2024

May 28, 2024

BioLineRx Q1 Success with APHEXDA® Growth - TipRanks

May 28, 2024

May 24, 2024

BioLineRx Showcases Promising Cancer Drug Trial Results - TipRanks

May 24, 2024

Apr 01, 2024

BiolineRx Ltd. Completes Significant Securities Offering - TipRanks

Apr 01, 2024